Follow Forum_Psych on Twitter
Search
 
 

Display results as :
 


Rechercher Advanced Search

Statistics
We have 222 registered users
The newest registered user is raheelmemon

Our users have posted a total of 1140 messages in 613 subjects
If you are seeing this, you have attempted to link to the UpToDate widget but are experiencing a problem. Please visit UpToDate for more information.
Share

Evaluation of the FDA Warning Against Prescribing Citalopram at Doses Exceeding 40 mg

View previous topic View next topic Go down

Evaluation of the FDA Warning Against Prescribing Citalopram at Doses Exceeding 40 mg

Post  Admin on Sat Aug 10, 2013 4:54 pm

Evaluation of the FDA Warning Against Prescribing Citalopram at Doses Exceeding 40 mg
Source: Am J Psychiatry 2013;170:642-650.

A recent Food and Drug Administration (FDA) warning cautioned that citalopram dosages exceeding 40 mg/day may cause abnormal heart rhythms, including torsade de pointes.
Source: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm



The authors assessed relationships between citalopram use and ventricular arrhythmias and mortality.

Method: A cohort study was conducted using Veterans Health Administration data between 2004 and 2009 from depressed patients who received a prescription for citalopram (N=618,450) or for sertraline (N=365,898), a comparison medication with no FDA warning. Cox regression models, adjusted for demographic and clinical characteristics, were used to examine associations of antidepressant dosing with ventricular arrhythmia and cardiac, noncardiac, and all-cause mortality.

Results:
- Citalopram daily doses >40 mg were associated with lower risks of ventricular arrhythmia (adjusted hazard ratio=0.68, 95% CI=0.61–0.76), all-cause mortality (adjusted hazard ratio=0.94, 95% CI=0.90–0.99), and noncardiac mortality (adjusted hazard ratio=0.90, 95% CI=0.86–0.96) compared with daily doses of 1–20 mg.
- Citalopram daily doses of 21–40 mg were associated with lower risks of ventricular arrhythmia (adjusted hazard ratio=0.80, 95% CI=0.74–0.86) compared with dosages of 1–20 mg/day but did not have significantly different risks of any cause of mortality.
- The sertraline cohort revealed similar findings, except there were no significant associations between daily dose and either all-cause or noncardiac mortality.

Conclusions:
This large study found no elevated risks of ventricular arrhythmia or all-cause, cardiac, or noncardiac mortality associated with citalopram dosages >40 mg/day. Higher dosages were associated with fewer adverse outcomes, and similar findings were observed for a comparison medication, sertraline, not subject to the FDA warning. These results raise questions regarding the continued merit of the FDA warning.

*****************
Click on to post your comments
avatar
Admin
Admin
Admin

Posts : 948
Points : 2102
Reputation : 0
Join date : 2011-02-19
Location : Philadelphia

http://psychiatry.find-forum.net

Back to top Go down

View previous topic View next topic Back to top

- Similar topics

 
Permissions in this forum:
You cannot reply to topics in this forum